10/16/2013 6:19:40 AM
THERAVECTYS raises €14.7 million
Paris, 16 October 2013 – THERAVECTYS, a French biotechnology company specialized in developing
vaccines using lentiviral vector technology, today announced the finalisation of a €14.7 million
financing round (US$20 million).
This financing round was completed by TETHYS, the holding company owned by the BETTENCOURT
family, alongside Financière IDAT (Philippe ODDO), FGP Capital and other private investors.
Becoming one of the leading players in vaccination
"We wish to give our warmest thanks to all the investors, both new and existing ones, for the
confidence they have shown by taking part in this financing round. This newly raised capital will allow
THERAVECTYS to become a leader in the fields of vaccination and immunotherapy. It will enable the
company to pursue the clinical development of its therapeutic anti-HIV vaccine, bring an oncology
vaccine candidate to clinical trial by 2015 and help in setting up strategic partnerships with
pharmaceutical firms", says Jean-Pierre KINET, Chairman of the THERAVECTYS Board of Directors.
As Chief Executive Officer Renaud VAILLANT puts it, "This investment materialises research done by
the entire THERAVECTYS team, which has worked for more than six years to develop its unique
expertise in lentiviral vector technology".
The world's first use of lentiviral vectors in the field of vaccines
"The THERAVECTYS development plan presented by the management team to shareholders in 2011
forecast the world's first use of lentiviral vectors in vaccination by late 2012", says John PIETERS, the
former CEO of AMGEN France and long-standing shareholder in THERAVECTYS. He adds, "And this
happened the end of 2012 with the start-up of the clinical trial of our therapeutic anti-HIV vaccine.
The team's ability to meet its deadlines and keep its commitments has persuaded me to invest in the
company for the third time."
A unique vaccine platform
Asked about the technological potential offered by THERAVECTYS, Sir Thomas McKILLOP, former
CEO of ASTRAZENECA and current independent director of THERAVECTYS says: "The phase I/II
clinical trial of a therapeutic anti-HIV vaccine currently under way highlights the unique potential of
the THERAVECTYS vaccine platform and opens the way to building a broad portfolio of products that
can rapidly be tested in clinical trials".
A biopharmaceutical company on an international scale
"By taking part in this financing round, the BETTENCOURT family supports the ambition at
THERAVECTYS to develop innovative therapeutic solutions to cover unmet medical needs and meet
the major challenges facing the public health system", explains Jean-Pierre MEYERS, CEO of TETHYS.
"Moreover, THERAVECTYS must continue to set up worldwide partnerships with research institutes
as well as pharmaceutical companies", he adds.
THERAVECTYS is a French biotechnology company that is developing a new generation of vaccines
based on lentiviral vector technology. This breakthrough technology came from fundamental
research at Institut Pasteur. It is expected to enable the prevention or effective treatment of many
diseases in which the induction of effective cellular immune response is required: viral diseases (HIV),
bacterial or parasitic diseases, cancers, etc. Since its creation, THERAVECTYS has been working to
develop a therapeutic anti-HIV vaccine whose phase I/II clinical trial is currently under way.
Benefiting from an exclusive world licence agreement with Institut Pasteur and financial support
from public authorities (Bpifrance, i.e. the former OSEO, and ANR), THERAVECTYS is continuing to
invest in research and development to fight against other pathologies. Alone or in collaboration with
other pharmaceutical players, THERAVECTYS plans shortly to begin developing new candidate
Romain Gohaud (CFO)
+33 1 43 90 19 20
Press Relations Contact ALIZE RP
Caroline Carmagnol and Christian Berg
+ 33 6 64 18 99 59 / + 33 1 70 22 53 86 / + 33 6 31 13 76 20
firstname.lastname@example.org / email@example.com
Help employers find you! Check out all the jobs and post your resume.
comments powered by